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Fluoroquinolone-
resistant
Streptococcus
pneumoniae
To the Editor: In pneumococci,
resistance to fluoroquinolones is asso-
ciated with chromosomal mutations in
the quinolone-resistance–determining
regions (QRDR) of type II topoiso-
merase enzymes, predominantly gyrA
and  parC. Several mutations have
been described in these enzymes, but
only a few have been shown by in
vitro studies to confer resistance:
S81F or Y, C, or I and E85K in gyrA;
E474K in gyrB; A63T, S79F or Y or L
and D83G or N in parC; and E474K
and D435N or H in parE (1–5). Other
frequently described mutations are
K137N in parC and I460V in parE,
which appear to not contribute to flu-
oroquinolone resistance because they
are commonly found in susceptible
strains, and no evidence exists for
their conferring fluoroquinolone
resistance in vitro. We describe here a
pneumococcal strain that was isolated
from a 66-year-old white man with
chronic obstructive pulmonary dis-
ease (COPD). 
The patient was admitted to the
hospital with a presumed exacerba-
tion of COPD. He had been dis-
charged from the hospital 2 days ear-
lier, having recovered from a similar
manifestation of this disease. His
treatment history was 250 mg/day
oral levofloxacin for 7 days while in
the hospital and levofloxacin for 10
days as an outpatient for a similar
lower respiratory tract infection 3
months earlier.
On this second admission he was
given levofloxacin, 250 mg intra-
venously, once a day. He was treated
with a low dosage because he was in
renal failure. The patient continued to
worsen and was transferred to the
intensive care unit, where ceftriaxone,
1 g intravenously once a day, was
given along with levofloxacin. He
improved on the combination therapy
and was discharged without sequelae.
Cultures of the patient’s blood and
sputum grew Streptococcus pneumo-
niae. The isolate from blood was
resistant to levofloxacin (MIC 8
mg/L) and ciprofloxacin (MIC 8
mg/L), yet susceptible to gatifloxacin
(MIC 1 mg/L) and ceftriaxone (MIC
0.38 mg/L), with intermediate resist-
ance to penicillin (MIC 1.5 mg/L).
The resistant isolate was of serotype
6A and of multilocus sequence type
376, which is the North Carolina6A-23
clone (http://www.sph.emory.edu/
PMEN/index.html).
Efflux testing that compared the
ciprofloxacin MICs in the presence
and absence of reserpine (10mg/L)
showed no evidence of an overex-
pressed efflux pump. We sequenced
the QRDRs (gyrA, gyrB, parC, parE)
and the entire gyrA and parC genes of
the resistant strain isolated from blood
by using previously described primers
(2). Sequencing showed a S79Y
mutation in parC and a Q118K
(CAA→AAA) mutation in gyrA.
Sequencing of the entire gyrA and
parC genes confirmed that no addi-
tional amino acid substitutions were
outside the QRDRs. The entire gyrA
gene PCR product was transformed
directly into the susceptible pneumo-
coccal reference strain R6 by a stan-
dard transformation protocol (4).
Transformants were selected on plates
containing increasing concentrations
of ciprofloxacin and, in a second step,
were transformed with the entire parC
gene of the resistant strain.
The ciprofloxacin and lev-
ofloxacin MICs of R6 transformed
with the gyrA gene of the resistant iso-
late containing the new Q118K muta-
tion were 4 and 2 mg/L, respectively.
After additional transformation of
these transformants with parC of the
resistant isolate containing the S79Y
mutation, the selected double trans-
formants exhibited the same MICs as
the original clinical isolate (8 mg/L
for ciprofloxacin and levofloxacin).
The transformation of parC alone
conferred an intermediate increase in
the MICs (ciprofloxacin 2 mg/L, lev-
ofloxacin 4 mg/L). All transformants
were confirmed by sequencing.
To determine the biologic cost
associated with the different resist-
ance mutations in vitro, each fluoro-
quinolone-resistant mutant was com-
peted against the fluoroquinolone-
susceptible parent strain R6 (with an
independent streptomycin resistance
marker) as described by Johnson et al.
(6). The outcome was evaluated as the
change in the ratios of the competing
strains as a function of the number of
generations. Each competition was
performed in triplicate by using inde-
pendent starting cultures of each com-
peting strain. Compared with the
wild-type R6 strain, the relative fit-
ness values for the gyrA, parC, and
double mutants were 1.06, 1.03, and
0.93, respectively.
These data indicate that a single
mutation in either parC or gyrA does
not impose a substantial fitness bur-
den. In contrast, the double-mutation
parC S79Y and  gyrA Q118K was
associated with a slower growth rate.
Similar results of relative fitness for
single (parC S79Y and  gyrA S81F)
and double mutations were observed
by Gillespie et al. (7).
Development of resistance to fluo-
roquinolones is a stepwise process,
involving spontaneous mutations in
the genes encoding the target enzymes
DNA gyrase and the topoisomerase
IV. Mutants with mutations in 1 of the
enzymes are estimated to arise at a
frequency of 1 to 10−7 (1). Therefore,
fluoroquinolone resistance due to
selection of spontaneous mutants dur-
ing treatment may be related to the
number of bacterial cells in the popu-
lation under selective pressure.
Patients with COPD are frequently
colonized by high bacterial loads.
COPD has been identified in several
recent studies as an independent risk
factor for fluoroquinolone resistance
(8,9). Low doses of fluoroquinolones
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may also lead to an increased risk for
resistance selection (10). Because the
Q118K mutation has not been previ-
ously described, this new mutation
was probably selected by the current
or antecedent treatments rather than
by an infection with a resistant widely
disseminated clone.
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Spring Scrub
Typhus, People’s
Republic of China 
To the Editor: Pingtan Island, in
the eastern Fujian Province, People’s
Republic of China, has been a tradi-
tional focus of summer scrub typhus.
In the early 1950s, the health of the
residents was compromised by scrub
typhus, with an incidence of 1,000
cases/100,000 population and a case-
fatality rate of 13.6%. With the under-
standing of the pathogen and applica-
tion of effective treatments (1,2), the
epidemic was brought under control.
Documentation showed that from
1960 through 1990, the annual inci-
dence of scrub typhus maintained a
level of 50–100 cases/year. Since
1990, cases have decreased sharply.
The usual epidemic season for
scrub typhus on the island was sum-
mer. The first outbreak of spring scrub
typhus occurred in 2000 in the town
of Beicuo; 10 cases were reported.
Beicuo, population 10,000, is located
in southwestern Pingtan Island. The
first patient visited the local hospital
on April 6, 2000, with a high fever,
cough, and headache. The initial
exclusion of scrub typhus because of
the spring time frame made the diag-
nosis difficult until a typical black
eschar was found on the patient’s
waist. This case called attention to
spring scrub typhus and led to the
timely diagnosis and treatment of the
subsequent cases. By 2005, a total of
28 spring cases were on file. An indi-
rect immunofluorescence antibody
method with Gilliam strain antigen, as
described (3,4), was applied to the
above samples for serologic analysis.
Samples with antibody titers >64
were considered diagnostic. All 28
case-patients were identified as hav-
ing antibodies to Orientia tsutsuga-
mushi 8–20 days after the onset of the
disease (Table).
The number of cases of spring
scrub typhus from 2000 to 2005 were
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